156 related articles for article (PubMed ID: 19619590)
1. Systemic delivery and preclinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitization.
Jeong SY; Park SJ; Yoon SM; Jung J; Woo HN; Yi SL; Song SY; Park HJ; Kim C; Lee JS; Lee JS; Choi EK
J Control Release; 2009 Nov; 139(3):239-45. PubMed ID: 19619590
[TBL] [Abstract][Full Text] [Related]
2. Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.
Ma X; Huang X; Moore Z; Huang G; Kilgore JA; Wang Y; Hammer S; Williams NS; Boothman DA; Gao J
J Control Release; 2015 Feb; 200():201-11. PubMed ID: 25542645
[TBL] [Abstract][Full Text] [Related]
3. Molecularly targeted gold nanoparticles enhance the radiation response of breast cancer cells and tumor xenografts to X-radiation.
Chattopadhyay N; Cai Z; Kwon YL; Lechtman E; Pignol JP; Reilly RM
Breast Cancer Res Treat; 2013 Jan; 137(1):81-91. PubMed ID: 23160926
[TBL] [Abstract][Full Text] [Related]
4. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers.
Motea EA; Huang X; Singh N; Kilgore JA; Williams NS; Xie XJ; Gerber DE; Beg MS; Bey EA; Boothman DA
Clin Cancer Res; 2019 Apr; 25(8):2601-2609. PubMed ID: 30617135
[TBL] [Abstract][Full Text] [Related]
5. NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer.
Li LS; Reddy S; Lin ZH; Liu S; Park H; Chun SG; Bornmann WG; Thibodeaux J; Yan J; Chakrabarti G; Xie XJ; Sumer BD; Boothman DA; Yordy JS
Mol Cancer Ther; 2016 Jul; 15(7):1757-67. PubMed ID: 27196777
[TBL] [Abstract][Full Text] [Related]
6. Assessment of various formulation approaches for the application of beta-lapachone in prostate cancer therapy.
Wu X; Kasselouri A; Vergnaud-Gauduchon J; Rosilio V
Int J Pharm; 2020 Apr; 579():119168. PubMed ID: 32087264
[TBL] [Abstract][Full Text] [Related]
7. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells.
Blanco E; Bey EA; Dong Y; Weinberg BD; Sutton DM; Boothman DA; Gao J
J Control Release; 2007 Oct; 122(3):365-74. PubMed ID: 17574288
[TBL] [Abstract][Full Text] [Related]
8. Nanotechnology-enabled delivery of NQO1 bioactivatable drugs.
Ma X; Moore ZR; Huang G; Huang X; Boothman DA; Gao J
J Drug Target; 2015; 23(7-8):672-80. PubMed ID: 26453163
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy.
Dong Y; Chin SF; Blanco E; Bey EA; Kabbani W; Xie XJ; Bornmann WG; Boothman DA; Gao J
Clin Cancer Res; 2009 Jan; 15(1):131-9. PubMed ID: 19118040
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation.
Dong Y; Bey EA; Li LS; Kabbani W; Yan J; Xie XJ; Hsieh JT; Gao J; Boothman DA
Cancer Res; 2010 Oct; 70(20):8088-96. PubMed ID: 20940411
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation.
Park HJ; Ahn KJ; Ahn SD; Choi E; Lee SW; Williams B; Kim EJ; Griffin R; Bey EA; Bornmann WG; Gao J; Park HJ; Boothman DA; Song CW
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):212-9. PubMed ID: 15629614
[TBL] [Abstract][Full Text] [Related]
12. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
Cao L; Li LS; Spruell C; Xiao L; Chakrabarti G; Bey EA; Reinicke KE; Srougi MC; Moore Z; Dong Y; Vo P; Kabbani W; Yang CR; Wang X; Fattah F; Morales JC; Motea EA; Bornmann WG; Yordy JS; Boothman DA
Antioxid Redox Signal; 2014 Jul; 21(2):237-50. PubMed ID: 24512128
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effects of radiation and beta-lapachone in DU-145 human prostate cancer cells in vitro.
Suzuki M; Amano M; Choi J; Park HJ; Williams BW; Ono K; Song CW
Radiat Res; 2006 May; 165(5):525-31. PubMed ID: 16669706
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells.
Choi EK; Terai K; Ji IM; Kook YH; Park KH; Oh ET; Griffin RJ; Lim BU; Kim JS; Lee DS; Boothman DA; Loren M; Song CW; Park HJ
Neoplasia; 2007 Aug; 9(8):634-42. PubMed ID: 17786182
[TBL] [Abstract][Full Text] [Related]
15. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.
Blanco E; Bey EA; Khemtong C; Yang SG; Setti-Guthi J; Chen H; Kessinger CW; Carnevale KA; Bornmann WG; Boothman DA; Gao J
Cancer Res; 2010 May; 70(10):3896-904. PubMed ID: 20460521
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles.
Qian Y; Qiu M; Wu Q; Tian Y; Zhang Y; Gu N; Li S; Xu L; Yin R
Sci Rep; 2014 Dec; 4():7490. PubMed ID: 25502402
[TBL] [Abstract][Full Text] [Related]
17. Administration of the optimized β-Lapachone-poloxamer-cyclodextrin ternary system induces apoptosis, DNA damage and reduces tumor growth in a human breast adenocarcinoma xenograft mouse model.
Seoane S; Díaz-Rodríguez P; Sendon-Lago J; Gallego R; Pérez-Fernández R; Landin M
Eur J Pharm Biopharm; 2013 Aug; 84(3):497-504. PubMed ID: 23333901
[TBL] [Abstract][Full Text] [Related]
18. β-Lapachone Induces NAD(P)H:Quinone Oxidoreductase-1- and Oxidative Stress-Dependent Heat Shock Protein 90 Cleavage and Inhibits Tumor Growth and Angiogenesis.
Wu Y; Wang X; Chang S; Lu W; Liu M; Pang X
J Pharmacol Exp Ther; 2016 Jun; 357(3):466-75. PubMed ID: 27048660
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2.
Huang W; Xing Y; Zhu L; Zhuo J; Cai M
Exp Cell Res; 2021 Sep; 406(1):112633. PubMed ID: 34089726
[TBL] [Abstract][Full Text] [Related]
20. Beta-lapachone suppresses radiation-induced activation of nuclear factor-kappaB.
Dong GZ; Oh ET; Lee H; Park MT; Song CW; Park HJ
Exp Mol Med; 2010 May; 42(5):327-34. PubMed ID: 20200474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
